Novo Nordisk's diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways

The drugs are on track to become some of the best-selling of all-time as pop culture, social media, and third-party marketers  cash in on the hype

Novo is currently treating about 500,000 US patients

Other companies specialising in parts of the manufacturing process for the injections are vying to get a bigger foothold by scaling up their capacity

Seizures of fake medication claiming to contain semaglutide, found in Ozempic and Wegovy, are increasing in Ireland

With the pandemic boom for makers of vaccines and testing kits unravelling, investors are turning their focus to sectors such as weight-loss drugs

Growth in second quarter in particular driven by an 'exceptionally strong Danish pharmaceutical sector', analyst says

Novo Nordisk's market value exceeds Denmark’s domestic economy on the back of its Wegovy diabetes and obesity drug

Study showing weight-loss drug cuts risk of heart attacks and strokes by a fifth saw share surge of 17%

The response to good news about an appetite-suppressing drug is muted only because people have been too ashamed to admit they have rather common conditions such as food obsession